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Abstract
The adaptor protein-2 sigma subunit (AP2σ2) is pivotal for clathrin-mediated endocytosis of plasmamembrane constituents such
as the calcium-sensing receptor (CaSR).Mutations of theAP2σ2Arg15 residue result in familial hypocalciuric hypercalcaemia type
3 (FHH3), a disorderof extracellular calcium (Ca2+o) homeostasis. To elucidate the role ofAP2σ2 in Ca
2+
o regulation,we investigated
65 FHH probands, without other FHH-associated mutations, for AP2σ2 mutations, characterized their functional consequences
and investigated the genetic mechanisms leading to FHH3. AP2σ2 mutations were identiﬁed in 17 probands, comprising
5 Arg15Cys, 4 Arg15His and 8 Arg15Leumutations. A genotype–phenotype correlationwas observed with the Arg15Leumutation
leading to marked hypercalcaemia. FHH3 probands harboured additional phenotypes such as cognitive dysfunction. All three
FHH3-causing AP2σ2 mutations impaired CaSR signal transduction in a dominant-negative manner. Mutational bias was
observed at the AP2σ2 Arg15 residue as other predicted missense substitutions (Arg15Gly, Arg15Pro and Arg15Ser), which also
caused CaSR loss-of-function, were not detected in FHH probands, and these mutations were found to reduce the numbers of
CaSR-expressing cells. FHH3 probands had signiﬁcantly greater serum calcium (sCa) and magnesium (sMg) concentrations with
reduced urinary calcium to creatinine clearance ratios (CCCR) in comparison with FHH1 probands with CaSR mutations, and a
calculated index of sCa × sMg/100 ×CCCR, whichwas≥ 5.0, had a diagnostic sensitivity and speciﬁcity of 83 and 86%, respectively,
for FHH3. Thus, our studies demonstrate AP2σ2 mutations to result in a more severe FHH phenotype with genotype–phenotype
correlations, and a dominant-negative mechanism of action with mutational bias at the Arg15 residue.
Introduction
Familial hypocalciuric hypercalcaemia (FHH) is an autosomal
dominant disorder of extracellular calcium (Ca2+o) homeostasis
characterized by lifelong mild-to-moderate elevations of serum
calcium concentrations,mild hypermagnesaemia, normal or ele-
vated circulating parathyroid hormone (PTH) concentrations and
inappropriately low urinary calciumexcretion [mean urinary cal-
cium to creatinine clearance ratio (CCCR) <0.01] (1–4). FHH is a
genetically heterogeneous disorder comprising three reported
variants. FHH types 1 and 2 (FHH1, OMIM #145980; FHH2, OMIM
#145981) are due to heterozygous loss-of-function mutations of
the calcium-sensing receptor (CaSR) and G-protein, Gα11, en-
coded by the CASR and GNA11 genes, respectively (5–9). CaSR
and Gα11 are widely expressed, including in the parathyroid
glands and kidneys, and play a pivotal role in Ca2+o homeostasis
by detecting alterations in Ca2+o concentrations and initiating
multiple intracellular signalling cascades that include phospho-
lipase C-mediated accumulation of inositol 1,4,5-trisphosphate
and increases in intracellular calcium (Ca2+i) concentrations
(10), which in turn lead to alterations in PTH secretion and
urinary calcium excretion. FHH type 3 (FHH3, OMIM #600740) is
associated with heterozygous loss-of-function mutations of
AP2S1, located on chromosome 19q13.3 (11–14).
AP2S1 encodes the σ2-subunit of the ubiquitously expre-
ssed heterotetrameric adaptor protein-2 (AP2) complex, which
also comprises α-, β2- and μ2-subunits. The AP2 complex is a
central component of clathrin-coated vesicles and facilitates
the endocytosis of plasma membrane constituents such as
G-protein-coupled receptors (GPCRs) (15–17). AP2S1 mutations
have been reported in 19 FHH patients and families to date, and
these all comprise heterozygous missense substitutions of the
AP2 σ2-subunit (AP2σ2) Arg15 residue (Arg15Cys, Arg15His and
Arg15Leu) (11,12,14). This Arg residue is located in a positively
charged region of AP2σ2 that binds to speciﬁc peptide motifs on
membrane cargo proteins (18). It is predicted that FHH3-causing
Arg15mutations disrupt binding of the AP2 complex to the intra-
cellular carboxyl terminus of the CaSR, thereby impairing endo-
cytosis of this GPCR (11). This hypothesis is supported by in vitro
expression studies that have demonstrated AP2S1 mutations to
affect CaSR cell-surface expression and signal transduction (11).
These studies of AP2S1 mutations have highlighted a role for
the AP2 endocytic complex in Ca2+o homeostasis. To date, 19
FHH3 patients have been reported with AP2σ2 mutations, com-
prising 8 Arg15Cys, 4 Arg15His and 7 Arg15Leu. To further eluci-
date the role and spectrumof AP2σ2mutations in the aetiology of
the phenotypic features of FHH3,we conducted studies to charac-
terise the structural/functional consequences of AP2σ2 muta-
tions together with their underlying genetic mechanisms in
additional FHH patients, who did not have CASR or GNA11muta-
tions. Our study identiﬁedAP2σ2mutations in 17 hypercalcaemic
probands and their families, and further analysis of these AP2σ2
mutants has revealed the presence of a genotype–phenotype
correlation, a mutational bias of the AP2σ2 Arg15 residue with a
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likely dominant-negative action and a clinical approach to differ-
entiate patients with FHH3 from those with FHH1.
Results
AP2S1 mutations and clinical phenotypes
DNA sequence analysis of the entire AP2S1 429-bp coding region
and 8 exon–intron boundaries was undertaken in 65 unrelated
FHH probands without CASR or GNA11 mutations (22 males and
43 females). This revealed the presence of AP2S1mutations in 17
probands (7 males and 10 females), thereby representing a >25%
AP2S1 mutation detection rate in this cohort of FHH patients
withoutCASR andGNA11mutations. The FHH3-associatedmuta-
tions only affected the AP2σ2Arg15 (R15) residue and consisted of
ﬁve Arg15Cys (R15C), four Arg15His (R15H) and eight Arg15Leu
(R15L) mutations (Table 1), all of which had previously been
reported to represent pathogenic mutations (11). Two unrelated
FHH3 female probands, aged 7 and 15 years, harboured Arg15Leu
mutations that were demonstrated to be absent in both of their
parents, and hence likely to be arising de novo (Fig. 1). Four
FHH3 subjects had symptoms attributable to hypercalcaemia, in-
cluding lethargy, constipation, widespreadmusculoskeletal pain
and polydipsia (Table 1). Eleven FHH3 probands had clinical fea-
tures in addition to hypercalcaemia and hypocalciuria (Table 1).
In particular, bone mineral density (BMD) was noted to be low
(T-score < −1.0 or Z-score <−2.0) at the lumbar spine or femoral
neck in 5 of 10 patients aged 14 to 64 years (Table 1). The low
BMD in all ﬁve patients was not associated with renal dysfunc-
tion, hyperparathyroidism, vitamin D deﬁciency or thyrotoxi-
cosis. Furthermore, seven FHH3 patients (aged 3–37 years) were
noted to have learning disabilities characterized by cognitive def-
icits and/or behavioural disturbances (Table 1). In addition, the
father of a proband with learning disabilities (06/13a, Table 1)
also had a cognitive deﬁcit in association with hypercalcaemia.
Two of the Arg15Leu probands with cognitive deﬁcits (02/03
and 02/11, Table 1) had short stature with height at or below
the third centile, and one of these probands (02/03, Table 1) was
found to harbour an atrial septal defect, whereas the other indi-
vidual (02/11, Table 1) suffered from recurrent episodes of pan-
creatitis. The pancreatitis in this patient was not due to
gallstones or alcohol abuse, and analysis of genes known to be as-
sociated with pancreatitis, such as SPINK1, CFTR, PRSS1 and CTRC
(19), did not reveal any mutations.
Genotype–phenotype correlations at the AP2σ2 Arg15
residue
We examined for phenotypic differences between patients with
Arg15Cys, Arg15His or Arg15LeuAP2S1mutations. Analysis of bio-
chemical and clinical dataavailable fora total of 27 FHH3probands
[17 from this study and 10 from our previously reported study (11)]
revealed that patients with the Arg15Leu mutation had signiﬁ-
cantly greater elevations of serum albumin adjusted-calcium
concentrations when compared with those with the Arg15Cys
and Arg15His AP2σ2 mutations (3.06 ± 0.04 mmol/l for Arg15Leu
versus 2.83 ± 0.03 mmol/l for Arg15Cys and 2.74 ± 0.03 mmol/l for
Arg15His, P < 0.01).Moreover, patientswith theArg15Cysmutation
had a signiﬁcantly greater hypercalcaemia (P < 0.05) than patients
harbouring the Arg15His mutation. Such differences were not
observed for other biochemical indices of mineral metabolism
(Fig. 2).
Table 1. Clinical and biochemical ﬁndings in 17 FHH probands with AP2S1 mutations
Serum Urine BMD
Mutation Patient Sex Family history Age at presentation/
diagnosis (years)
Associated
clinical features
Caa,b Pic Mgd ALPe,f PTHg,h CCCRi,j LS FN
Arg15Cys
19/12a M Yes 48 Nil 2.94a – 0.82 110e 45.0g 0.009i −1.0k −2.9k
03/13a M Yes 22 H 2.96a 0.82 – 98e 41.0g 0.004i – –
16/13 M Yes 37 H, L 2.80a 0.76 1.02 68e 50.0g 0.003i −1.6k −0.2k
07/14 F Yes 16 B 1.50b 1.22 0.95 39e 44.0g 0.004i −1.2k −1.4k
11/14 M – 3 L 2.90a 1.09 0.91 368f 60.0g 0.004i – –
Arg15His
08/11 F Yes 33 H 2.76a 0.85 0.99 74e 7.4h 0.010i −2.1k −1.7k
03/12 F Yes 44 Nil 2.80a 0.86 – 65e 5.2h 0.009i 0.0k −0.4k
19/12b F – 19 – 2.74a 0.65 – 104e 4.6h 0.005i – –
03/13b M Yes 64 Nil 2.72a – – 103e 6.0h – −0.6l −1.1l,m
Arg15Leu
02/03 F No 15 A, L, S 2.90a 0.86 1.03 – 4.7h 0.015i −4.6k –
13/08 F No <1o L 3.01a 0.99 – 242f 15.0g – – –
02/11 F – 14 L, P, S 3.20a 1.2 1.02 88e 31.0g 0.005i −3.0k −2.5k
04/11 M – 11 L 3.00a 0.60 0.89 314f 50g 0.004i −1.4k −1.4k
09/12 F – 9 – 2.81a 1.0 0.97 298f 96g 0.002i
06/13a M Yes 9 L 3.10a 0.78 – 249f 38g 0.27j – –
06/13b F No 7 Nil 3.03a 0.87 0.95 285f 40.5g 0.001i −1.3k,n N
02/14 F No 26 H 2.95a 1.17 0.98 – 4.0h 0.008i – –
Normal serum ranges (6): albumin adjusted-calcium, a2.10–2.60mmol/l; ionized calcium, b1.19–1.35mmol/l; phosphate (Pi), c0.70–1.40 mmol/l; magnesium (Mg), d0.70–1.0
mmol/l; total alkaline phosphatase (ALP) activity, e30–130 U/l, f70–330 U/l; PTH, g10–65 ng/l; h1.3–7.6 pmol/l. Normal urine ranges; calcium-to-creatinine clearance ratio
(CCCR), i>0.02; calcium-to-creatinine ratio, j0.3–0.7. kBMD Z-scores are provided for subjects of <50 years old and lBMD T-scores are provided for subjects of >50 years
old; mforearm BMD T-score = −2.5 for proband 03/13b; nwhole-body BMD Z-score = −2.0 for proband 06/13b; odiagnosed in early infancy. A, atrial septal defect; B,
irritable bowel syndrome co-segregating with hypercalcaemia in family 07/14; FN, femoral neck; H, hypercalcaemic symptoms; L, mild-to-moderate learning
disability; LS, lumbar spine; N, normal; S, short stature (height <third centile); P, pancreatitis;—, not known.
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Phenotypic differences between FHH3 and FHH1
To determinewhether FHH3 is associatedwith any differences in
the biochemical phenotype when compared with FHH1, we ana-
lysed the serum and urine biochemistry from 51 FHH3 subjects
that included affected members of the previously reported
multi-generational FHH3 kindreds from Oklahoma (FHHOK) and
Northern Ireland (FHHNI) (20–23), and 43 previously reported
FHH1 probands, who all harboured CASR mutations (8). This re-
vealed FHH3 patients to have a greater degree of hypercalcaemia
than the FHH1 patients (serum adjusted-calcium = 2.87 ± 0.02
mmol/l for FHH3 versus 2.76 ± 0.02 mmol/l for FHH1, P < 0.001)
(Fig. 3). FHH3 patients when compared with FHH1 patients
also had signiﬁcantly marked hypermagnesaemia (serum
magnesium = 1.04 ± 0.02 mmol/l for FHH3 versus 0.95 ± 0.02
mmol/l for FHH1, P < 0.01) andhypocalciuria (CCCR = 0.004 ± 0.001
for FHH3 versus 0.007 ± 0.001 for FHH1, P < 0.01) (Fig. 3). There
were no signiﬁcant differences in the serum concentrations of
phosphate, alkaline phosphatase (ALP) activity or PTH between
the FHH3 and FHH1 patients (Fig. 3). As serum adjusted-calcium,
serum magnesium and CCCR values were signiﬁcantly different
between FHH3 and FHH1 patients, we investigated whether the
combined use of these biochemical parameters could be utilized
to discriminate between these two hypercalcaemic disorders.
Based on the observation that serum adjusted-calcium (sCa)
and serum magnesium (sMg) values are elevated, whereas
CCCR is reduced in FHH3, a calculated index (sCa × sMg/100 ×
CCCR), designated CMCR, was determined for each of the sub-
jects in the FHH1 and FHH3 groups (Fig. 3) with all biochemical
parameters beingmeasured inmillimole per litre. Receiver–oper-
ator curve (ROC) analysis of the CMCR index (Fig. 3) revealed an
area-under-the curve (AUC) of 0.85 (P < 0.001) and an optimal
cut-off value of 5.0 for discriminating between FHH3 and FHH1,
which provides a diagnostic sensitivity of 83% [95% conﬁdence
interval (CI) = 61–95] and speciﬁcity of 86% (95% CI = 57–98), and
positive and negative predictive values of 90% (95% CI = 70–98)
and 80% (95% CI = 52–95), respectively.
Analysis of AP2σ2 codon 15 mutation bias
The present study has identiﬁed 17 hypercalcaemic patientswith
AP2S1 mutations that all affected the AP2σ2 Arg15 residue, and
previous studies have reported 19 AP2S1mutations that all affect
the Arg15 residue (11,12,14) yielding a total of 36 FHH3-causing
mutations identiﬁed to date. These 36AP2S1mutations involving
substitutions of Arg15 comprise 13 Arg15Cys, 8 Arg15His and 15
Arg15Leu. Analysis of the DNA sequence of the Arg15 codon re-
veals it to be CGC indicating thatmissense substitutions affecting
the ﬁrst or second nucleotides would be predicted to be non-syn-
onymous and lead to one of six possible amino acid substitu-
tions, which comprise Cys, Gly, His, Leu, Pro and Ser (Fig. 4).
This expected observation of six different amino acid substitu-
tions contrasts signiﬁcantly (P < 0.0001, Chi-squared test) with
the three Arg15-mutant substitutions observed in FHH3 patients.
To investigate the potential occurrence of the Arg15Cys,
Arg15His and Arg15Leu, and the absence of Arg15Gly, Arg15Pro
and Arg15Ser variants, we assessed the effects of all six potential
Arg15 mutants on the structure and function of AP2. Analysis of
the AP2 complex crystal structure predicted that all the six Arg15
missense substitutions, including the Arg15Gly, Arg15Pro and
Arg15Ser variants that have not been observed in FHH3, would
impair AP2 complex function by disrupting a key polar contact
between the AP2 complex and the cargo protein dileucine recog-
nition motif (Fig. 4). Thus, all the six Arg15 missense substitu-
tions would signiﬁcantly alter the structure, and we therefore
determined their functional consequences on CaSR activity, by
expressing them in HEK293 cells that stably expressed the CaSR
Figure 1.Detection of de novo AP2S1mutations in families 02/03 and 06/13b. (A) DNA sequence analyses of the probands (arrowed) revealed a G-to-T transversion at codon
15, predicted to result in amissense amino acid substitution of Arg to Leu, and loss of aHhaI restriction endonuclease site. (B) Restrictionmap showing thatHhaI digestion
would result in two products of 143 and 252 bp from the wild-type (WT) sequence, but would not affect the mutant (m) sequence. PCR and HhaI digestion revealed the
probands [individual II.4 of family 02/03 (C) and individual II.1 of family 06/13b (D)] to be heterozygous for theArg15Leumutation. The absence of theArg15Leumutation in
the unaffected parents of both probands is consistent with the mutation arising de novo.
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(HEK-CaSR) (9,11). Transient transfection of the wild-type or mu-
tant AP2S1-pBI-CMV4-RFP expression constructs, or vector con-
taining the red ﬂuorescence protein (RFP) reporter gene alone,
was undertaken in the HEK-CaSR cells (9,11). Expression of the
CaSR and RFP, which represents a surrogate of AP2σ2 expression,
was detected by immunoﬂuorescence and western blotting of
whole-cell lysates (Fig. 5), and the responses of Ca2+i concentra-
tions to alterations in Ca2+o concentrations were then assayed
by ﬂow cytometry (9,11).
HEK-CaSR cells expressing each of the six Arg15 missense
AP2σ2 variants (i.e. the three observed Arg15Cys, Arg15His and
Arg15Leu and the three non-observed Arg15Gly, Arg15Pro and
Arg15Ser AP2σ2 variants) were found to have half-maximal ef-
fective concentration (EC50) values that were signiﬁcantly higher
(P < 0.0001) than cells expressing the wild-type AP2σ2 protein.
Thus, the three non-observed Arg15 AP2σ2 variants decreased
the sensitivity of HEK-CaSR cells to Ca2+o concentrations in a
similar manner to the three FHH3-causing AP2σ2 mutations
(Fig. 5 and Table 2). However, cells expressing the non-observed
Arg15Gly, Arg15Pro or Arg15Ser AP2σ2 mutants were found to
have signiﬁcantly reduced increases in cell numbers over a 24-h
period, when comparedwith cells expressing wild-type or FHH3-
mutant AP2σ2 proteins (Fig. 5). These results indicate that the
Arg15Gly, Arg15Pro and Arg15Ser AP2σ2 mutants are likely not
observed as they are associated with an impairment of cell
growth, when compared with wild-type or the FHH3-associated
mutant AP2σ2 proteins (Fig. 5 and Supplementary Material,
Fig. S1).
Figure 2. Assessment of genotype–phenotype correlations between probands harbouring Arg15His (R15H), Arg15Cys (R15C) or Arg15Leu (R15L) AP2S1mutations. Serum
and urine biochemical values are shown as scatter plots. (A) Probandswith R15Lmutations had signiﬁcantly greater elevations of serumadjusted-calciumconcentrations
than probands with R15C or R15H mutations. Probands with R15C mutations were signiﬁcantly more hypercalcaemic than probands with R15H mutations. (B–F) No
signiﬁcant differences in serum concentrations of phosphate, magnesium, ALP activity, PTH or urinary CCCR were observed between probands harbouring each of the
three AP2S1 R15 mutations. Mean values for the respective groups are indicated by horizontal solid lines. The normal ranges [mean ± 2 standard deviations (SDs)] for
serum calcium, phosphate and magnesium are indicated by the grey areas. The upper limit of normal (ULN) for the assay that was used for serum ALP activity and
PTH concentrations are represented by the broken line. For CCCR, the lower limit (<0.01) for the consideration of hypocalciuria is represented by the broken line.
*P < 0.05, **P < 0.01.
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Dominant-negative effects of AP2S1 mutations
FHH3 is associated with heterozygous loss-of-function AP2σ2
mutations, and these could be causing the disease by either
haploinsufﬁciency (i.e. a reduced dosage of the wild-type AP2σ2
protein) or dominant-negative effects on the heterotetrameric
AP2 complex. To investigate these genetic mechanisms, we stud-
ied the effects of altering the dosage of wild-type and mutant
Figure 3. Comparison of biochemical phenotypes between FHH1 and FHH3. Scatter plots of serum concentrations of (A) adjusted-calcium, (B) phosphate, (C) magnesium,
(D) ALPactivity, (E) PTH, (F) urinary CCCRand (G) CMCR index,which is calculated as sCa × sMg/100 × CCCR, for FHH3probands are shown. Suchbiochemical values arealso
provided for an age- and gender-matched cohort of previously reported FHH1 probandswith CASRmutations (8). All biochemical parameters comprising the CMCR index
were measured in millimole per litre. FHH3 probands, when compared with FHH1 probands, had signiﬁcantly greater elevations of serum adjusted-calcium and
magnesium concentrations, reduced CCCR values and elevated CMCR. Mean values for the respective groups are indicated by horizontal solid lines. The normal
ranges (mean ± 2 SDs) for serum calcium, phosphate and magnesium are indicated by the grey areas. The ULN for the assay that was used for serum ALP activity and
PTH concentrations are represented by the broken line. For CCCR, the lower limit (<0.01) for the consideration of hypocalciuria is represented by the broken line. For
CMCR index, the cut-off value of 5.0, above which a diagnosis of FHH3 should be considered, is represented by the broken line. (H) ROC of discriminatory power of
CMCR index to distinguish between FHH3 and FHH1. The CMCR had an AUC of 0.85, which was signiﬁcantly greater than that of the reference line (P < 0.001). **P < 0.01,
***P < 0.001.
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AP2σ2 proteins on the EC50 responses of HEK-CaSR cells that were
transiently transfected with wild-type or mutant AP2S1-pBI-
CMV4-RFP expression constructs. We used the bidirectional
AP2S1-pBI-CMV4-RFP vector as it expresses RFP and AP2σ2 at
equivalent levels, thereby enabling RFP expression to be used as
a surrogate for AP2σ2 expression (9). We selected populations of
Figure 4. Observed and predicted mutations at the AP2S1 Arg15 (R15) residue. (A) Schematic representation of possible nucleotide and amino acid substitutions affecting
codon 15. Substitutions affecting theﬁrst or secondnucleotide of codon 15 (CGC) are predicted to lead to one of six possible non-synonymousmutations or variants,which
are Cys15 (TGC), Gly15 (GGC), His15 (CAC), Leu15 (CTC), Pro15 (CCC) or Ser15 (AGC). Substitutions affecting the third nucleotide of the CGC triplet are predicted to lead to
synonymous variants only. (B) Crystal structure of the α-subunit (green) and σ2-subunit (blue) of the AP2 heterotetrameric complex bound to an acidic (Gln-containing)
dileucine cargo protein motif [PDB ﬁle 2JKR (18)]. The key polar contacts (black dashed lines) between the σ2-subunit Arg15 residue (σArg15, red) and α-subunit Arg21
residue (αArg21, grey), and a Gln residue located four residues from the ﬁrst Leu residue of the acidic dileucine motif [Gln(Leu-4), orange], are shown. (C–G) Structural
analysis of six potential Arg15 mutations demonstrating that the observed mutants (Cys15, His15 and Leu15) and non-observed mutants (Gly15, Pro15 and Ser15) are
all predicted to result in the loss of the key polar contact with the cargo protein Gln (Leu-4) residue.
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cells with increasing levels of RFP expression by ﬂow cytometry
(Fig. 6) and assessed the effects of altering wild-type and mutant
AP2σ2 dosage by measuring the Ca2+i responses of the HEK-CaSR
cells to changes in Ca2+o concentrations, and determining the lin-
ear regression of mean EC50 values against expression levels of
wild-type and mutant AP2σ2 proteins. In this experiment, loss-
of-function mutations with dominant-negative actions, which
would exert greatereffectswith increasingprotein concentrations,
will show a positive correlation between mutant protein
concentration and EC50. However, loss-of-function mutations as-
sociated with haploinsufﬁciency would not exert effects on the
wild-type protein, whose concentration would remain constant,
and hence therewould be absent correlation betweenmutant pro-
tein concentrations and EC50 values (Fig. 6).
The results of such linear regression analyses revealed that
increased expression levels of FHH3-causing Arg15-mutant
AP2σ2 proteins progressively impaired the sensitivity of HEK-
CaSR cells, as highlighted by a signiﬁcantly positive relationship
Figure 5. Functional expression of AP2S1Arg15 (R15) mutants. (A) Fluorescencemicroscopy of HEK293 cells stably transfected with CaSR and transiently transfected with
wild-type R15 (WT-R15), and FHH3-associatedmutants (Cys15, C15; His15, H15; Leu15, L15) or other possible R15mutants (Fig. 4) (Gly15, G15; Pro15, P15; Ser15, S15), or pBI-
CMV4-RFP expression vector only (V). RFP expression in these cells indicates successful transfection and expression by these constructs. Bar indicates 20 μm. (B) Western
blot analysis of whole-cell lysates using anti-CaSR, anti-GAPDH and anti-RFP antibodies. The FHH3-mutant AP2σ2 and predicted possible R15 mutant proteins were
expressed at similar levels. UT, untransfected cells. (C) Measurement of Ca2+i responses following stimulation with varying Ca
2+
o concentrations revealed cells
expressing observed FHH3-associated mutants or the non-observed possible R15 mutants (Fig. 4) to have signiﬁcantly raised EC50 values when compared with cells
expressing the wild-type AP2σ2 (WT-R15) protein. Results are from eight to ten assays and three independent transfections. (D) Growth of cells expressing WT or
mutant AP2σ2 proteins. Cells expressing the non-observed possible R15 mutants showed a signiﬁcantly reduced percentage increase in cell numbers over a 24-h
period when compared with cells expressing WT or FHH3-associated mutant AP2σ2 proteins, consistent with an impairment of proliferation. Results are from 11 to 18
assays and 4 independent transfections. *P < 0.05 and †P < 0.0001.
Table 2. EC50 values of observed and non-observed AP2σ2 Arg15 mutants
AP2σ2 construct EC50 (m)
Mean value 95% CI N P-value (versus WT)
pBI-CMV4 vector 2.85 2.80–2.89 10 NS
Wild-type AP2σ2 2.77 2.74–2.81 10 —
Observed AP2σ2 mutants
Arg15His 3.02 2.96–3.08 9 <0.0001
Arg15Cys 3.03 2.98–3.07 10 <0.0001
Arg15Leu 3.07 3.01–3.13 10 <0.0001
Non-observed AP2σ2 mutants
Arg15Gly 2.99 2.94–3.04 9 <0.0001
Arg15Pro 2.92 2.85–2.98 8 <0.0001
Arg15Ser 2.94 2.89–3.00 8 <0.0001
The number (N) of replicate experiments from three independent transfections is indicated.
NS, not signiﬁcant; CI, conﬁdence interval.
5086 | Human Molecular Genetics, 2015, Vol. 24, No. 18
 at U
niversity of D
undee on June 30, 2016
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
Figure 6. Comparison of EC50 values for HEK-CaSR cells transfected with increasing amounts of wild-type (WT) or mutant AP2S1-pBI-CMV4-RFP expression constructs.
(A) During ﬂow cytometry, ﬂuorescence over a 1–10 000 range can be detected. The ﬁrst large peak represents cells not expressing RFP but displaying low levels of auto-
ﬂuorescence. Cells displaying increased ﬂuorescencewith respect to this population reﬂect those expressing RFP. Cells from ﬁve different RFP ﬂuorescenceswere selected
on the basis ofmeanﬂuorescence (gate 1 logmeanﬂuorescence = 50–100, gate 2 logmeanﬂuorescence = 125–250, gate 3 logmeanﬂuorescence = 500–1000, gate 4 logmean
ﬂuorescence = 1250–2500 and gate 5 logmean ﬂuorescence = 5000–10000), consistent with a ﬂuorescence ranging frombetween 1- and 100-fold over baseline, i.e. between
gate 1 and gate 5, which represent the lowest and the highest levels of RFP ﬂuorescence, and therefore AP2σ2, respectively. (B) Predicted linear regressions of mean EC50
with effects owing to dominant-negative and haploinsufﬁciencymutants. Loss-of-functionmutants with dominant-negative effects on theWT protein will exert greater
effects on EC50 valueswith increasing concentrations (red line), whereas loss-of-functionmutants associatedwith haploinsufﬁciency of theWT proteinwill not affect the
EC50 values with increasing concentrations as the EC50 will depend on the concentration of WT protein, which will remain constant (blue line). (C–E) Linear regression of
the mean EC50 of cells with increasing levels of AP2σ2 expression demonstrate no signiﬁcant deviation from zero in cells transfected with the WT-R15 AP2S1-pBI-CMV4-
RFP expression construct (r2 = 0.07, P = 0.67), whereas a signiﬁcantly positive incline to the slope is observed in cells transfected with the mutant AP2S1-pBI-CMV4-RFP
expression constructs (C15 r2 = 0.82, P < 0.05; H15 r2 = 0.84, P < 0.05; L15 r2 = 0.99, P < 0.0001), thereby indicating that FHH3-associated AP2σ2 mutations may act in a
dominant-negative manner. All experiments were conducted on N = 8 separate occasions.
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between the expression levels of all three AP2σ2mutants and the
mean cellular EC50 responses (Cys15 r
2 = 0.82, P < 0.05; His15 r2 =
0.84, P < 0.05; Leu15 r2 = 0.99, P < 0.0001), but that increased ex-
pression levels of wild-type AP2σ2 had no effect on EC50 values
(r2 = 0.07, P = 0.67) (Fig. 6). These ﬁndings indicate a potential
dominant-negative effect of the FHH3-causing Arg15 AP2σ2
mutants.
Discussion
Our results, which have identiﬁed AP2S1 mutations that only
result in missense substitutions of the Arg15 residue in 17 add-
itional FHH probands, have helped to establish a genotype–
phenotype correlation between AP2σ2 mutants and the severity
of hypercalcaemia; devise an index based on measurements of
plasma calcium and magnesium concentrations and urinary
clearances of calcium and creatinine to differentiate between
FHH1 and FHH3; elucidate the occurrence of a mutational bias
at the AP2σ2 Arg15 residue in FHH3 patients and deﬁne the likely
genetic mechanism for AP2σ2 mutations as being a dominant-
negative action in causing FHH3. In addition, our study shows
that FHH3 can be associated with de novo AP2S1 mutations, con-
sistent with a previous report (12), thereby indicating that pa-
tients may not have a family history of the disorder and that
AP2S1 mutations may be associated with non-familial forms of
hypercalcaemia and hypocalciuria.
The identiﬁcation by this study of AP2S1mutations in 17 add-
itional probands with FHH3, together with ours and other previ-
ous reports (11,12,14), yields a total of 36 probands with such
AP2σ2 mutations, which all involve the Arg15 residue and result
in 1 of 3 missense substitutions comprising Arg15Cys, Arg15His
and Arg15Leu. Our analyses of these subjects reveal genotype–
phenotype correlations for these AP2σ2 mutations, in which
the Arg15Leu mutation is associated with the most pronounced
hypercalcaemia, whereas Arg15His is associated with the mild-
est increase in serum calcium concentrations. This is surprising
and themechanisms underlying these genotype–phenotype cor-
relations are unclear, as three-dimensionalmodelling and in vitro
functional expression studies indicate that all three Arg15 AP2σ2
mutations disrupt CaSR activity to a similar extent (11), and the
basis for the differences between our in vivo clinical observations
and in vitro results remains to be elucidated.
Our study has also revealed phenotypic differences between
FHH1 and FHH3. In particular, FHH3 was associated with signiﬁ-
cantly greater elevations of serum calcium, and >20% of FHH3 pa-
tients in this cohort had symptomatic hypercalcaemia. These
ﬁndings arenot typical of FHH,which is considered to be a benign
and asymptomatic disorder, and in general associated with
serum calcium concentrations that remain within 10% of the
upper limit of the normal range (1). In addition to themore severe
hypercalcaemia, FHH3 was associated with more pronounced
suppression of urinary calcium excretion than FHH1. The more
marked serum and urinary calcium phenotype of FHH3 contrasts
with the results of in vitro studies that indicate FHH3-causing
AP2S1 mutations to lead to a milder shift in the set point of
CaSR-expressing cells when compared with FHH1-causing CASR
mutations (11). Theseﬁndings suggest that AP2σ2mutationsmay
inﬂuence Ca2+o homeostasis through effects on cell membrane
proteins other than the CaSR. Indeed, the renal thick ascending
limb Na+/K+/2Cl− (NKCC2) transporter, which is pivotal for urin-
ary calcium reabsorption, has been demonstrated to be regulated
by clathrin-mediated endocytosis (24). Other phenotypic differ-
ences between FHH3 and FHH1 included the occurrence of low
BMD and cognitive dysfunction in FHH3. Low BMD occurred in
ﬁve FHH3 probands with AP2S1 mutations whereas patients
with FHH1, owing to CASR mutations, have been reported to
have normal bone resorption rates and BMD measurements at
the spine, hip and forearm (25). Cognitive dysfunction was ob-
served in seven FHH3 probands, four of which presented with
serum calcium concentrations of >3.0 mmol/l, and exposure to
marked hypercalcaemia in infancy or childhood may have led
to developmental delay and adversely affected neurological de-
velopment in these individuals (26). It is also possible that expres-
sion of mutant AP2σ2 subunits within the brain may directly
inﬂuence neurological development, consistent with the role of
the AP2 complex inmediating receptor trafﬁckingwithin neuron-
al synapsesof thehippocampus (27), a region of thebrain required
for memory acquisition and spatial orientation. The Arg15Leu
AP2S1 mutation was also associated with recurrent pancreatitis
in one FHH3proband, aﬁnding consistentwith FHH1, inwhich re-
current pancreatitis has occasionally been reported (28). However,
FHH1 probands with pancreatitis typically harbour heterozygous
mutations of both the CASR and serine protease inhibitor, Kazal
type 1 (SPINK1) genes (29). In contrast, the affected FHH3 proband
did not harbour a mutation of SPINK1 or other genes associated
with pancreatitis (19), and this proband’smarked hypercalcaemia
may have been sufﬁcient to disrupt pancreatic function. Given
these possible phenotypic differences between FHH3 and FHH1,
we sought to design an index based on clinical biochemistry
tests of serum and urine that would help to differentiate the
two disorders. The ﬁndings that FHH3 is associated with greater
elevations in serum calcium and magnesium concentrations,
and reductions in urinary calcium excretion, when compared
with FHH1, led us to design the calcium–magnesium–calcium
clearance ratio (CMCR), calculated as sCa × sMg/100 × CCCR. As-
sessment of the performance characteristics of this index indi-
cated that FHH patients with CMCR ≥5.0 were signiﬁcantly more
likely to have FHH3. Thus, the CMCR index may have utility in
the clinical setting for directing FHH patients for either CASR or
AP2S1 gene analysis, with patients having a CMCR value of ≥5.0
being prioritized for AP2S1 analysis (Fig. 7). However, ∼30% of
FHH3 patients have CMCR values that overlap with that of FHH1
patients (Fig. 3), and combined analysis of the CASR, AP2S1 and
GNA11 genes is suggested in individuals with CMCR values of
<5.0 (Fig. 7). No correlation was observed between the CMCR
index and codon 15 genotype of the FHH3 patients. The CMCR
index requires further validation in studies of other populations
and using alternate biochemical assays.
The ﬁnding that all the 36 reported FHH3 patients, of which 17
are from this study, harbour either an Arg15Cys, Arg15His or
Arg15Leu mutation, highlights the importance of this evolution-
ary conserved residue for AP2-mediated Ca2+o homeostasis
(11,12,14). Furthermore, the absence of the other possible
missense substitutions at this codon (Arg15Gly, Arg15Pro or
Arg15Ser) indicates mutation bias at the AP2σ2 Arg15 residue.
Our in vitro characterization of the non-observed Gly15, Pro15 or
Ser15 mutations demonstrated these mutant AP2σ2 proteins to
be expressed and to result in an impairment of CaSR activity.
However, the Gly15, Pro15 or Ser15 mutants had additional dele-
terious effects that led to a reduction in the numbers of cells
expressing these mutants. These ﬁndings indicate a potential
role for the AP2 complex in cell growth or viability and are con-
sistent with a previously reported study of mice harbouring
a germline ablation of the AP2μ2 subunit, which led to early
embryonic lethality, thus highlighting the involvement of the
ubiquitously expressed AP2 complex in mammalian develop-
ment (30). Thus, a possible explanation for the absence of the
Arg15Gly, Arg15Pro and Arg15Ser AP2σ2 mutations in patients
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is that these deleteriousmutations likely result in embryonic le-
thality, whereas the FHH3-causing AP2σ2 mutations Arg15Cys,
Arg15His and Arg15Leu are observed in patients, as thesemuta-
tions are not associated with deleterious effects on cell growth,
but are tolerated and compatiblewith embryonic and post-natal
survival.
Our ﬁndings of a likely dominant-negative effect of FHH3-
causing Arg15 AP2σ2mutations are consistentwith previousmu-
tagenesis studies of theAP2 complex (31). Indeed, overexpression
of a mutated μ2-subunit (AP2μ2), which displayed diminished
capacity to bind to some cargo proteins, has been reported to in-
hibit receptor trafﬁcking in a dominant-negative manner (31).
The precise mechanisms of such dominant-negative actions re-
main to be established but three possibilities are (1) the incorpor-
ation of a mutant σ2 subunit may impair the assembly of the
tetrameric complex, (2) incorporation of the mutant σ2 subunit
may alter the structure of the AP2 complex and hinder the
efﬁciency of wild-type AP2α, AP2β and AP2μ subunits (32) and
(3) the mutant AP2 complex may potentially sequester the CaSR
at the plasma membrane and prevent wild-type AP2 molecules
from effectively trafﬁcking this GPCR.
In summary, our studies of AP2S1mutations, which highlight
FHH3 as a distinct disorder of Ca2+o homeostasis and demon-
strate the importance of the AP2σ2 Arg15 residue for AP2 function,
have revealed genotype–phenotype correlations with mutation
bias at the Arg15 residue, as well as a likely dominant-negative
mechanism of action.
Materials and Methods
Subjects
Informed consentwas obtained from individuals, using protocols
approved by the local and national ethics committees (MREC/02/
Figure 7. Clinical approach to distinguishing between FHH1 and FHH3 in a hypercalcaemic patient. sCa, serum calcium; sMg, serummagnesium; sPTH, serum PTH; CCCR,
calcium to creatinine clearance ratio; CMCR = sCa × sMg/100 × CCCR; PHPT; primary hyperparathyroidism. *In a hypercalcaemic patient with normal/raised sPTH, a CCCR
of <0.01 is consistent with a diagnosis of FHH, provided that thiazide diuretic use, vitamin D deﬁciency and renal impairment have been excluded.
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2/93). Sixty-ﬁve unrelated probands (22 males and 43 females)
were ascertained. The age at diagnosis or presentation ranged
from early infancy to 76 years, and all probands had hypercalcae-
mia with normal or elevated PTH concentrations, in association
with inappropriately low urinary calcium excretion. Previous
mutational analysis of CASR and GNA11 had not identiﬁed any
abnormalities of the coding regions and exon–intron boundaries
of these genes (8,9).
DNA sequence analysis
Leukocyte DNA was extracted from venous blood samples and
quantiﬁed using the High sensitivity Qubit system (Invitrogen)
(11). AP2S1-speciﬁc primers were used to perform PCR ampliﬁca-
tion of the ﬁve exons and eight intron-exon boundaries of the
AP2S1 gene, as previously reported (11). DNA sequence analysis
of the PCR products was performed using the BigDye Terminator
v3.1 Cycle Sequencing Kit (Life Technologies) and an ABI auto-
mated capillary sequencer (Applied Biosystems), as reported (8).
DNA sequence abnormalities and co-segregation in familieswere
conﬁrmed by restriction endonuclease analysis (New England
Biolabs), as described (11).
Computer modelling of the AP2 structure
The crystal structure of the AP2 heterotetramer bound to an acid-
ic dileucine peptide has been reported previously (18). The
PyMOL Molecular Graphics System (version 1.2r3pre, Schrö-
dinger) was used to model the effect of the FHH3-associated
AP2σ2 mutations on the interaction with the acidic dileucine
motif peptide using the three-dimensional structure of AP2 ar-
chived in the Protein Data Bank at the European Bioinformatics
Institute with the accession number 2JKR (8,9,11,18). The effect
of the Arg15Cys, Arg15Leu, Arg15His, Arg15Pro, Arg15Ser and
Arg15Gly mutations on the interaction of AP2σ2 subunit with
the acidic dileucine peptide was modelled using PyMod plug-in
and Modeller.21 (9).
Generation of AP2S1 expression constructs
AnAP2σ2 expression construct was generated by cloning the full-
length AP2S1 coding region into the bidirectional cloning vector
pBI-CMV4-RFP (Clontech), which allows for co-expression of
AP2σ2 and RFP at equivalent levels (11,33). The use of RFP mini-
mized overlap between the emission spectra of this reporter
gene and the indo-1-AM Ca2+-binding ﬂuorophore. AP2S1 muta-
tions were introduced into the construct by site-directed muta-
genesis (QuikChange Lightning, Stratagene) and conﬁrmed by
DNA sequence analysis, as described (8,11).
Cell culture and transfection
Functional studies of AP2S1 mutations were performed in
HEK293 cells that stably expressed the CaSR (11). HEK293 cells
were used because suitable parathyroid and renal tubular cells
are not available, and HEK293 cells have been established as a
model for such studies (8,9,11,34). The reported stably CaSR-
transfected HEK293 cell line (HEK-CaSR) (9,11) was cultured in
high-glucose DMEM (Invitrogen) supplemented with 10% fetal
bovine serum and 1% geneticin (11). A high level of CaSR expres-
sion in these cells was conﬁrmed by western blot analysis of
whole-cell protein extract using a mouse monoclonal antibody
to human CaSR (ADD; Abcam, ab19347, 1:1000) (9,11). The wild-
type and mutant AP2σ2 constructs were transiently transfected
into HEK-CaSR cells using Lipofectamine 2000 (Invitrogen)
(9,11). Expression of RFP was used as a surrogate for AP2σ2 ex-
pression as it is expressed at equivalent levels to AP2σ2 by the
pBI-CMV4-RFP bidirectional vector (11). Western blot analysis of
cellular protein extract was undertaken using a rabbit polyclonal
antibody to RFP (Thermo Scientiﬁc, PA1-986, 1:500) (11). The
membrane was re-probed with mouse anti-GAPDH antibody
(Abcam, ab8245, 1:3000) as a loading control. Successful transfec-
tion was also conﬁrmed by visualising RFP ﬂuorescence using an
Eclipse E400 ﬂuorescence microscope with an epiﬂuorescence
ﬁlter, and images were captured using a DXM1200C digital
camera and NIS Elements software (Nikon) (9,11). The effect of
mutant AP2σ2 proteins on cell growthwas assessed by determin-
ing the percentage increase in cell numbers over a 24-h period, as
follows. Twenty-four hours after transfection, equal numbers of
cells were seeded into a 96-well plate, and the cells were imaged,
at 48 and 72 h, using ﬂuorescence microscopy, as mentioned
above (9,11). Following blinding to both transfection and time
point, the numbers of transfected cells were counted manually
at 48 and 72 h post-transfection, and the percentage increase in
cells determined using Microsoft Excel and statistical analysis
undertaken in GraphPad Prism (GraphPad) (9,11).
Measurement of Ca2+i responses
The effect of mutant AP2σ2 proteins on CaSR-mediated Ca2+i re-
sponses were assessed by determining EC50 values (i.e. [Ca
2+]o re-
quired for 50% of the maximal response) and comparing these to
thewild-type EC50, as reported (8,9,11). Brieﬂy, 48 h after transfec-
tion, the cells were harvested, washed in calcium- and magne-
sium-free Hank’s balanced salt solution (HBSS) (Invitrogen) and
loaded with 1 μg/ml indo-1-acetoxymethylester (Indo-1-am)
(Molecular Probes) for 1 h at 37 °C (8,9,11). After the removal of
free dye, the cells were resuspended in calcium- and magne-
sium-free HBSS andmaintained at 37°C. Flow cytometry was per-
formedwith a Beckman Coulter MoFlo XDP equippedwith JDSUY
Xcyte UV Laser and a Coherent Sapphire 488 Laser using a 550LP
dichroic mirror and 580/30 bandpass ﬁlter. Single cells were iso-
lated from debris on the basis of morphology using forward scat-
ter and side scatter readings (8,9,11). Cells were stimulated by
sequentially adding calcium to the calcium- and magnesium-
free HBSS to progressively increase the [Ca2+]o from 0 to 15 m.
The baseline ﬂuorescence ratio was measured for 2 min, the
ﬂuorescence ratio compared with the time was recorded and
datawere collected for 2 min at each [Ca2+]o. Cytomation Summit
software was used to determine the peak mean ﬂuorescence
ratio of the transient response after each individual stimulus ex-
pressed as a normalized response (8,9,11). Analysis of ﬁve separ-
ate populations of cells gated for increasing RFP as a concordant
surrogate for increasing AP2σ2 expression was undertaken and
concentration–response curves generated using the normalized
response at each of nine different [Ca2+]o (0–15 m) for each sep-
arate experiment. Nonlinear regression of the concentration–
response curveswas performedwith GraphPad Prism (GraphPad)
to calculate the EC50 for each separate experiment (9,11). Subse-
quent linear regression of the mean EC50 (N = 8 experiments) for
each AP2S1-pBI-CMV4-RFP expression vector was undertaken
with GraphPad Prism (GraphPad) (9,11).
Statistical analyses
The phenotypic data from this study were pooled with those of
our previous studies of FHH3 patients and families (11,20,23).
To undertake a comparison of phenotypes between FHH3 and
FHH1, we used data from 43 previously reported unrelated
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FHH1 probands (13 males and 30 females, aged 1–84 years) who
had germline heterozygous CASR mutations (8). Comparisons of
continuous variables between two groupswere undertaken using
the Mann–Whitney U test, and the Kruskal–Wallis test was used
to comparemultiple groups. Categorical variables were analysed
using the Chi-squared test. ROC analysis using values of the
CMCR sensitivity and speciﬁcity was performed to study the dis-
criminatory power of the CMCR index to distinguish between
FHH1 and FHH3. Comparisons of EC50 values were performed
using the F test, as described (9,11). The Mann–Whitney U test
was used to compare the proliferation rates of cells expressing
wild-type or mutant AP2σ2 proteins. All analyses were under-
taken using GraphPad Prism (GraphPad) and are presented
as mean ± SEM unless otherwise stated. A value of P < 0.05 was
considered signiﬁcant for all analyses.
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